Developer docs
API playgroundTry for free, no card

Search company profiles

aTyr Pharma

Full company profile

uuid0000eld

Namestring
aTyr Pharma
Legal namestring
aTyr Pharma Inc.
Websiteurl
atyrpharma.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

aTyr Pharma is a clinical-stage biotherapeutics company founded in 2005 and headquartered in San Diego, California, that translates tRNA synthetase biology into novel protein therapeutics for fibrosis and inflammation. Its proprietary platform comprises a library of 300+ protein compositions derived from all 20 human cytosolic tRNA synthetases, protected by 220+ issued or allowed patents across 21 patent families. The company's lead candidate, efzofitimod (ATYR1923), is a first-in-class immunomodulator derived from a splice variant of histidyl-tRNA synthetase that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve inflammation without immune suppression.

In September 2025, the global Phase 3 EFZO-FIT study of efzofitimod in 268 pulmonary sarcoidosis patients failed to meet its primary endpoint, triggering an 83% stock decline and multiple securities class action lawsuits. The company has requested an FDA Type C meeting for mid-April 2026 to determine the regulatory path forward, and continues to run the Phase 2 EFZO-CONNECT study in systemic sclerosis-related ILD. Earlier-stage assets include ATYR0101 (DARS-derived, LTBP1-binding) and ATYR0750 (AARS-derived, FGFR4 ligand) for fibrosis indications, and the Pangu BioPharma subsidiary in Hong Kong is developing bispecific antibodies targeting NRP2 for cancer in collaboration with HKUST.

The business model is that of a pre-revenue clinical-stage biotech: aTyr funds development through equity raises (most recently ~$30.7M via Jefferies in August 2025 and a $50M public offering in February 2023) and intends to generate revenue through commercialization of efzofitimod following regulatory approval, with Kyorin Pharmaceutical holding Japan rights. The company has not established product pricing. Future commercial GTM relies on specialty pharmacy distribution and physician outreach for interstitial lung disease, with orphan-designated indications in pulmonary sarcoidosis and SSc-ILD representing the addressable patient base of over 500,000 in the US and over 3 million globally.

Short descriptiontext

aTyr Pharma is a clinical-stage biotherapeutics company developing protein therapeutics derived from tRNA synthetase biology for fibrosis and inflammation, with lead candidate efzofitimod in development for interstitial lung diseases including pulmonary sarcoidosis and SSc-ILD.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
interstitial lung disease therapeutics, biologics drug development, fibrosis treatment pipeline, tRNA synthetase biologics, immunomodulator therapeutics
Industry4 codes
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biotechnology company, aTyr Pharma is pre-revenue and focused on developing therapeutic candidates through clinical trials. The company expects to generate revenue through eventual commercialization of efzofitimod and other pipeline candidates upon regulatory approval.

atyrpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1EFZO-FIT
Description

Phase 3 clinical trial name for efzofitimod in pulmonary sarcoidosis

atyrpharma.com
+1 more record
Core offering1 text field

aTyr Pharma is a clinical-stage biotherapeutics company developing tRNA synthetase-derived protein biologics for fibrosis and inflammation. Its lead candidate, efzofitimod (ATYR1923), is an immunomodulator in Phase 3 development for pulmonary sarcoidosis and Phase 2 for systemic sclerosis-related ILD (EFZO-CONNECT). The pipeline additionally includes ATYR0101 and ATYR0750, fusion proteins targeting fibrosis and FGFR4-mediated pathways respectively.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 3 EFZO-FIT study enrolled 268 patients with symptomatic pulmonary sarcoidosis across US, Europe, Japan and Brazil
+2 more records
Product overview1 text field

aTyr Pharma is a clinical-stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. The company's product portfolio centers on efzofitimod (ATYR1923), a novel biologic immunomodulator derived from histidyl-tRNA synthetase that selectively modulates myeloid cells through neuropilin-2. Efzofitimod is the lead candidate in Phase 3 development for pulmonary sarcoidosis and Phase 2 for systemic sclerosis-related ILD. The broader pipeline includes ATYR0101 (a DARS-derived LTBP1 modulator for fibrosis) and ATYR0750 (an AARS-derived FGFR4 modulator for liver disorders), both in preclinical stages. The company operates through its Pangu BioPharma subsidiary in Hong Kong for antibody discovery and maintains an extensive intellectual property portfolio covering over 300 protein compositions derived from all 20 tRNA synthetases.

Product and service3 records
1Efzofitimod (ATYR1923)
CategoryLead therapeutic candidate
Description

A novel biologic immunomodulator and lead therapeutic candidate derived from a naturally occurring splice variant of histidyl-tRNA synthetase (HARS) that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve inflammation without immune suppression and potentially prevent fibrosis progression. In clinical development for pulmonary sarcoidosis (Phase 3 EFZO-FIT) and systemic sclerosis-related ILD (Phase 2 EFZO-CONNECT).

2ATYR0101
CategoryPipeline candidate
Description

A fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS) that binds to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates TGF-beta. Early data suggest ATYR0101 exerts antifibrotic effects by inducing apoptosis of myofibroblasts. Being developed for multiple fibrotic diseases including pulmonary fibrosis, systemic sclerosis, and liver and kidney fibrosis.

3ATYR0750
CategoryPipeline candidate
Description

A fusion protein derived from a domain of alanyl-tRNA synthetase (AARS) that acts as a novel ligand to fibroblast growth factor receptor 4 (FGFR4). FGFR4 is involved in cellular processes including cell proliferation, differentiation and tissue repair, with a role in inflammation and fibrosis particularly in liver diseases.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Kyorin Pharmaceutical holds partnership rights for the development and commercialization of efzofitimod for interstitial lung disease (ILD) in Japan. This regional partnership provides local regulatory and commercial expertise for the Japanese market.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with HKUST for basic and translational research in tRNA synthetase biology. The collaboration, supported by Hong Kong government's Innovation and Technology Commission through a two-year grant, focuses on developing a high-throughput platform for bispecific antibody development targeting Neuropilin-2 (NRP2) for cancer applications. Milestones achieved include establishing an innovative antibody discovery platform and developing a novel single-cell antibody discovery approach.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration for translating the tRNA synthetase platform into new drug candidates for fibrosis and inflammation.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing therapeutics for fibrosis and inflammation. Comparable in therapeutic focus area, clinical-stage profile, and small-cap public status to aTyr.

TypeDirect peer
Description

Clinical-stage biotech developing integrin-based therapeutics for idiopathic pulmonary fibrosis and other fibrotic diseases. Direct competitor in ILD/fibrosis with similar clinical-stage risk profile.

TypeBroad incumbent
Description

Established pulmonary and ILD-focused biopharma commercializing products in PAH and pulmonary fibrosis. Comparable as ILD therapeutic developer with broader portfolio and commercial reach.

TypeDirect peer
Description

European biotech with a significant IPF and ILD franchise (historical JAK/tyk2 programs). Comparable as a fibrosis-focused clinical-stage player with similar late-stage trial exposure.

5Prometheus Biosciences
TypeEmerging player
Description

Clinical-stage immunology biotech (acquired by Merck in 2023) developing precision therapeutics for immune-mediated diseases. Comparable in immunology mechanism focus and clinical-stage biotech profile.

TypeEmerging player
Description

Clinical-stage biotech developing immunology therapeutics for rare and autoimmune diseases. Comparable as small-cap immunology biotech with similar clinical execution requirements.

7ChemoCentryx
TypeEmerging player
Description

Late-stage rare immunology biotech (acquired by Amgen for $3.7B in 2022) that developed TAVNEOS. The Head of Commercial at aTyr previously led TAVNEOS commercial strategy here — directly comparable small-cap rare-disease immunology developer.

8Boehringer Ingelheim
TypeBroad incumbent
Description

Large pharma with nintedanib (OFEV) approved for IPF, SSc-ILD, and progressive fibrosing ILD. Represents the incumbent therapeutic standard against which efzofitimod must compete in ILD.

TypeBroad incumbent
Description

Major biopharma with pirfenidone (Esbriet) approved for IPF and active immunology pipeline. Incumbent ILD therapeutic competitor with broad development resources.

10Horizon Therapeutics
TypeBroad incumbent
Description

Specialty biopharma focused on rare and autoimmune diseases (acquired by Amgen). Comparable as a rare-disease immunology commercial-stage player that represents the type of strategic acquirer relevant to aTyr.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

aTyr Pharma

Biopharmaceutical Therapeuticsatyrpharma.com

aTyr Pharma is a clinical-stage biotherapeutics company developing protein therapeutics derived from tRNA synthetase biology for fibrosis and inflammation, with lead candidate efzofitimod in development for interstitial lung diseases including pulmonary sarcoidosis and SSc-ILD.

What aTyr Pharma does

aTyr Pharma is a clinical-stage biotherapeutics company founded in 2005 and headquartered in San Diego, California, that translates tRNA synthetase biology into novel protein therapeutics for fibrosis and inflammation. Its proprietary platform comprises a library of 300+ protein compositions derived from all 20 human cytosolic tRNA synthetases, protected by 220+ issued or allowed patents across 21 patent families. The company's lead candidate, efzofitimod (ATYR1923), is a first-in-class immunomodulator derived from a splice variant of histidyl-tRNA synthetase that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve inflammation without immune suppression.

In September 2025, the global Phase 3 EFZO-FIT study of efzofitimod in 268 pulmonary sarcoidosis patients failed to meet its primary endpoint, triggering an 83% stock decline and multiple securities class action lawsuits. The company has requested an FDA Type C meeting for mid-April 2026 to determine the regulatory path forward, and continues to run the Phase 2 EFZO-CONNECT study in systemic sclerosis-related ILD. Earlier-stage assets include ATYR0101 (DARS-derived, LTBP1-binding) and ATYR0750 (AARS-derived, FGFR4 ligand) for fibrosis indications, and the Pangu BioPharma subsidiary in Hong Kong is developing bispecific antibodies targeting NRP2 for cancer in collaboration with HKUST.

The business model is that of a pre-revenue clinical-stage biotech: aTyr funds development through equity raises (most recently ~$30.7M via Jefferies in August 2025 and a $50M public offering in February 2023) and intends to generate revenue through commercialization of efzofitimod following regulatory approval, with Kyorin Pharmaceutical holding Japan rights. The company has not established product pricing. Future commercial GTM relies on specialty pharmacy distribution and physician outreach for interstitial lung disease, with orphan-designated indications in pulmonary sarcoidosis and SSc-ILD representing the addressable patient base of over 500,000 in the US and over 3 million globally.

aTyr Pharma firmographics

Firmographics
Name
aTyr Pharma
Legal name
aTyr Pharma Inc.
Website
https://atyrpharma.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
aTyr Pharma is a clinical-stage biotherapeutics company developing protein therapeutics derived from tRNA synthetase biology for fibrosis and inflammation, with lead candidate efzofitimod in development for interstitial lung diseases including pulmonary sarcoidosis and SSc-ILD.
Ownership category
akta.pro rank

aTyr Pharma industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Interstitial lung disease therapeutics
  • Biologics drug development
  • Fibrosis treatment pipeline
  • TRNA synthetase biologics
  • Immunomodulator therapeutics

Where aTyr Pharma is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

aTyr Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Development and Commercialization: As a clinical-stage biotechnology company, aTyr Pharma is pre-revenue and focused on developing therapeutic candidates through clinical trials. The company expects to generate revenue through eventual commercialization of efzofitimod and other pipeline candidates upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

aTyr Pharma product offering

Product offering

Core offering

aTyr Pharma is a clinical-stage biotherapeutics company developing tRNA synthetase-derived protein biologics for fibrosis and inflammation. Its lead candidate, efzofitimod (ATYR1923), is an immunomodulator in Phase 3 development for pulmonary sarcoidosis and Phase 2 for systemic sclerosis-related ILD (EFZO-CONNECT). The pipeline additionally includes ATYR0101 and ATYR0750, fusion proteins targeting fibrosis and FGFR4-mediated pathways respectively.

Product overview

aTyr Pharma is a clinical-stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. The company's product portfolio centers on efzofitimod (ATYR1923), a novel biologic immunomodulator derived from histidyl-tRNA synthetase that selectively modulates myeloid cells through neuropilin-2. Efzofitimod is the lead candidate in Phase 3 development for pulmonary sarcoidosis and Phase 2 for systemic sclerosis-related ILD. The broader pipeline includes ATYR0101 (a DARS-derived LTBP1 modulator for fibrosis) and ATYR0750 (an AARS-derived FGFR4 modulator for liver disorders), both in preclinical stages. The company operates through its Pangu BioPharma subsidiary in Hong Kong for antibody discovery and maintains an extensive intellectual property portfolio covering over 300 protein compositions derived from all 20 tRNA synthetases.

Differentiator

Problem solved

Functional benefit

Brands

  • EFZO-FIT: Phase 3 clinical trial name for efzofitimod in pulmonary sarcoidosis
  • EFZO-CONNECT

Products and services

  • Efzofitimod (ATYR1923) A novel biologic immunomodulator and lead therapeutic candidate derived from a naturally occurring splice variant of histidyl-tRNA synthetase (HARS) that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve inflammation without immune suppression and potentially prevent fibrosis progression. In clinical development for pulmonary sarcoidosis (Phase 3 EFZO-FIT) and systemic sclerosis-related ILD (Phase 2 EFZO-CONNECT).
  • ATYR0101 A fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS) that binds to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates TGF-beta. Early data suggest ATYR0101 exerts antifibrotic effects by inducing apoptosis of myofibroblasts. Being developed for multiple fibrotic diseases including pulmonary fibrosis, systemic sclerosis, and liver and kidney fibrosis.
  • ATYR0750 A fusion protein derived from a domain of alanyl-tRNA synthetase (AARS) that acts as a novel ligand to fibroblast growth factor receptor 4 (FGFR4). FGFR4 is involved in cellular processes including cell proliferation, differentiation and tissue repair, with a role in inflammation and fibrosis particularly in liver diseases.

Quantifiable outcome

  • Phase 3 EFZO-FIT study enrolled 268 patients with symptomatic pulmonary sarcoidosis across US, Europe, Japan and Brazil
  • +2 more outcomes

Companies that use aTyr Pharma

Customer profile

Segments2 records

Ideal customer profiles3 records

aTyr Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

aTyr Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Kyorin Pharmaceutical Co., Ltd.coreChannel Partner/ Reseller/ DistributorKyorin Pharmaceutical holds partnership rights for the development and commercialization of efzofitimod for interstitial lung disease (ILD) in Japan. This regional partnership provides local regulatory and commercial expertise for the Japanese market.
  • Hong Kong University of Science and Technology (HKUST)coreStrategic or Co-development PartnerResearch collaboration with HKUST for basic and translational research in tRNA synthetase biology. The collaboration, supported by Hong Kong government's Innovation and Technology Commission through a two-year grant, focuses on developing a high-throughput platform for bispecific antibody development targeting Neuropilin-2 (NRP2) for cancer applications. Milestones achieved include establishing an innovative antibody discovery platform and developing a novel single-cell antibody discovery approach.
  • Dualsystems Biotech AGminorStrategic or Co-development PartnerCollaboration for translating the tRNA synthetase platform into new drug candidates for fibrosis and inflammation.

Scale indicators7 records

Recent moves5 records

Expansion highlights6 records

aTyr Pharma competitors and assessment

Company assessment

Direct peers

  • FibroGen: Clinical-stage biopharmaceutical company developing therapeutics for fibrosis and inflammation. Comparable in therapeutic focus area, clinical-stage profile, and small-cap public status to aTyr.
  • Pliant Therapeutics: Clinical-stage biotech developing integrin-based therapeutics for idiopathic pulmonary fibrosis and other fibrotic diseases. Direct competitor in ILD/fibrosis with similar clinical-stage risk profile.
  • Galapagos NV: European biotech with a significant IPF and ILD franchise (historical JAK/tyk2 programs). Comparable as a fibrosis-focused clinical-stage player with similar late-stage trial exposure.

Broad incumbents

  • United Therapeutics: Established pulmonary and ILD-focused biopharma commercializing products in PAH and pulmonary fibrosis. Comparable as ILD therapeutic developer with broader portfolio and commercial reach.
  • Boehringer Ingelheim: Large pharma with nintedanib (OFEV) approved for IPF, SSc-ILD, and progressive fibrosing ILD. Represents the incumbent therapeutic standard against which efzofitimod must compete in ILD.
  • Roche / Genentech: Major biopharma with pirfenidone (Esbriet) approved for IPF and active immunology pipeline. Incumbent ILD therapeutic competitor with broad development resources.
  • Horizon Therapeutics: Specialty biopharma focused on rare and autoimmune diseases (acquired by Amgen). Comparable as a rare-disease immunology commercial-stage player that represents the type of strategic acquirer relevant to aTyr.

Emerging players

  • Prometheus Biosciences: Clinical-stage immunology biotech (acquired by Merck in 2023) developing precision therapeutics for immune-mediated diseases. Comparable in immunology mechanism focus and clinical-stage biotech profile.
  • Kiniksa Pharmaceuticals: Clinical-stage biotech developing immunology therapeutics for rare and autoimmune diseases. Comparable as small-cap immunology biotech with similar clinical execution requirements.
  • ChemoCentryx: Late-stage rare immunology biotech (acquired by Amgen for $3.7B in 2022) that developed TAVNEOS. The Head of Commercial at aTyr previously led TAVNEOS commercial strategy here — directly comparable small-cap rare-disease immunology developer.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

aTyr Pharma social profiles

Digital presence

aTyr Pharma compliance and trust

Trust signal

Compliance1 record

aTyr Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

aTyr Pharma leadership team

Management profile

Number of profiles

Profiles12 records

aTyr Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

aTyr Pharma funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

aTyr Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about aTyr Pharma

What does aTyr Pharma do?

aTyr Pharma is a clinical-stage biotherapeutics company developing tRNA synthetase-derived protein biologics for fibrosis and inflammation. Its lead candidate, efzofitimod (ATYR1923), is an immunomodulator in Phase 3 development for pulmonary sarcoidosis and Phase 2 for systemic sclerosis-related ILD (EFZO-CONNECT). The pipeline additionally includes ATYR0101 and ATYR0750, fusion proteins targeting fibrosis and FGFR4-mediated pathways respectively.

Is aTyr Pharma a public or private company?

aTyr Pharma is a public company. It is classified as public and is currently operating.

When was aTyr Pharma founded?

aTyr Pharma was founded in 2005. It employs 51 to 100 people.

Where is aTyr Pharma based?

aTyr Pharma is headquartered in San Diego, United States, in the North America region.

How does aTyr Pharma make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are aTyr Pharma's main competitors?

Direct peers on record are FibroGen, Pliant Therapeutics and Galapagos NV. Broad incumbents are United Therapeutics, Boehringer Ingelheim, Roche / Genentech and Horizon Therapeutics. Emerging players are Prometheus Biosciences, Kiniksa Pharmaceuticals and ChemoCentryx.

Does aTyr Pharma have an API?

No public API is recorded for aTyr Pharma.

What industry is aTyr Pharma in?

aTyr Pharma's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooaTyr Pharma (ATYR) Stock Fair Value Moves Lower As Phase III Funding Risks LoomaTyr Pharma's fair value fell from about $114.29 to $45.17 per share, reflecting a more cautious view of execution and funding risks for Phase III trials of efzofitimod. RBC Capital lowered its split-adjusted price target to $6, while Freedom Broker downgraded the stock to Hold.Stock TitanaTyr Pharma to Participate in Two Investor ConferencesaTyr Pharma will participate in two investor conferences in November and December 2026, one in London and one in New York. The company will hold a fireside chat with CEO Sanjay S. Shukla at the Piper Sandler conference, with a webcast and replay available.Dealroom.coaTyr Pharma opens $80M share-sale program to extend runwayaTyr Pharma opened an at-the-market share-sale program on November 6, 2026, to sell up to $80 million. The financing follows a Phase 3 trial miss in pulmonary sarcoidosis, with a new Phase 3 design aligned with the FDA. The company expects Phase 2 results in Q2 2027.TradingViewaTyr Pharma Files Supplement for Up to $79.99 Million Stock OfferingaTyr Pharma filed a prospectus supplement to offer and sell up to $79,994,251 of common stock under its Open Market Sale Agreement with Jefferies LLC. The supplement was filed under a Form S-3 shelf registration statement declared effective on August 18, 2025, and includes a legal opinion on the legality of the shares.TradingViewRBC Capital maintains aTyr Pharma at Sector Perform, lowers price target to $6 from $40RBC Capital maintained aTyr Pharma at Sector Perform and lowered its price target to $6 from $40, an 85% cut. The new target is roughly in line with the Nov 5 close of $6.03.FinanzNachrichten.deNo Brainer Club trotzt dem Markt: +33% Tradingprofit innerhalb 24 HandelsstundenNo Brainer Club members earned a +33% trading profit within 24 trading hours on two biotech rebound trades. The gains came from aTyr Pharma and Minerva Neurosciences, achieved through precise timing and consistent risk management by chief analyst Maximilian.Investing.comPiper Sandler lowers aTyr Pharma stock price target on valuationPiper Sandler lowered its price target on aTyr Pharma to $35 from $280, maintaining an Overweight rating. The biotech trades at $6.03, down over 80% in a year, and holds $50.3 million in cash. The company also announced a 1-for-40 reverse stock split effective October 28.American Banking and Market NewsaTyr Pharma (NASDAQ:ATYR) Stock Lifted to “Hold” by Wall Street ZenWall Street Zen upgraded aTyr Pharma to a hold, while Weiss Ratings downgraded it from sell (d-) to sell (e+). The stock opened at $4.94, down 8% from Friday, and the company reported a loss of $4.40 EPS, beating the consensus estimate of $4.86. Analysts forecast a fiscal-year loss of $17.80 EPS.American Banking and Market NewsaTyr Pharma (NASDAQ:ATYR) & CRISPR Therapeutics (NASDAQ:CRSP) Head-To-Head ReviewCRISPR Therapeutics outperforms aTyr Pharma on 10 of 14 factors, including profitability, risk, analyst ratings, and valuation. CRISPR's consensus target price of $65.75 implies a 34.16% upside, while aTyr's beta of 0.91 indicates lower volatility. CRISPR's lower price-to-earnings ratio makes it the more affordable stock.TradingViewaTyr Pharma, Inc. Stock 12‑Month Price Target Raised to $3.2, Implies 1757% UpsideAnalysts' average price target for aTyr Pharma rose to $3.2 from $2.83, implying about 1757% upside from the Oct. 21 close. The consensus remains Buy across seven analysts, with forecasts ranging from $1 to $7 per share.